RO-3306 ,> = 98 %

Non disponible en dehors du Royaume-Uni et de l'Irlande

Application

RO-3306 has been used:To study the significance of CA4-mediated cytotoxicity in mitotic arrest In cell cycle synchronization to conduct a study on proteomics As a CDK1 inhibitor, to prevent early mitotic entry

Biochem/physiol Actions

RO-3306 is a selective ATP-competitive inhibitor of CDK1. It inhibites CDK1 cyclin B1 activity with Ki of 35 nM, nearly 10-fold selectivity relative to CDK2/cyclin E and over 50-fold relative to CDK4/cyclin D. RO-3306 has been used to cause cell cycle arrest at the G2/M boundary.

CDK1 (cyclin dependent kinase 1) is considered to be the “master switch” in cell division, which maintains the mitotic state of cells.

Features and Benefits

This compound is featured on the CDKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Packaging

5, 25 mg in glass bottle